Form SC 13G/A Mylan N.V. Filed by: WELLINGTON MANAGEMENT GROUP LLP
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 9/22/2026
- S&P 500, Dow set for higher open with focus on Mideast developments
- AI and earnings keep driving markets as focus shifts to Trump-Xi summit
- Meta bull case increasingly playing out, Mizuho says
- Oil falls to two-week low as Gulf supply outlook improves
- Don’t expect a grand bargain from the Trump-Xi summit: Yardeni
- Pennsylvania measles cases near 800 as outbreak grows
- A timeline of Trump administration moves to weaken endangered species protections
- Meta AI agent ‘Muse’ triggers massive tech rally as chips and Wall Street soar
- Nasdaq notches record-high close, AI optimism reignites and Treasury yields retreat
- SpaceX and Tesla’s AI linkup is getting deeper. Here’s what Morgan Stanley sees
S&P Affirms Ratings on Mylan (MYL) Following Meda AB Acquisition Announcement
February 12, 2016 8:10 AM ESTStandard & Poor's Ratings Services said it affirmed its 'BBB-' corporate credit rating and all existing issue-level ratings on Mylan N.V. (Nasdaq: MYL). The outlook is stable.
Mylan has announced it is acquiring Sweden-based pharmaceutical maker Meda AB for $9.9 billion, which includes the debt at Meda. The acquisition adds more than $2 billion in annual sales of generic, branded, and over-the-counter drugs to Mylan, strengthens its European franchise, and expands Mylan into a several new territories.
"Although the transaction, funded with... More
